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Background: The aim of this study was to determine factors associated with the severity of cancer related fatigue
(CRF) and predictors of improvement of CRF at the first follow-up visit in patients with advanced cancer referred to
outpatient palliative care clinic (OPC).
Methods: We reviewed the records of consecutive patients with advanced cancer presenting to OPC. Edmonton
Symptom Assessment System (ESAS) scores were obtained at the initial and subsequent visits between January
2003 and December 2008. All patients received interdisciplinary care led by palliative medicine specialists following
an institutional protocol. Fatigue improvement was defined as a reduction of ≥2 points in ESAS score relative to
the baseline. Descriptive statistics were used to summarize patient characterstics. Univariate analyses were
performed and only significant variables were included in multivariate regression analysis to determine factors
associated with severity and improvement in CRF.
Results: A total of 1778 evaluable patients were analyzed (median age, 59 years; 52% male). The median time between
visits was 15 days. Median fatigue scores on the ESAS were 6 at baseline and 5 at follow-up. Severity of all ESAS items
and low serum albumin were associated with fatigue at baseline (p < 0.0001). The improvement of fatigue was observed
in 586 patients (33%). The hierarchical model showed that fatigue improved over time (b = −0.009; p = 0.0009). low
appetite (odds ratio [OR] = 1.09 per point; p = 0.0113) and genitourinary cancer (OR = 1.74 per point; p = 0.0458) were
significantly associated with improvement of fatigue.
Conclusions: CRF is strongly associated with physical and emotional symptoms. Genitourinary cancer and low appetite
at baseline were associated with successful improvement of fatigue.
Keywords: Fatigue, Advanced cancer, Outpatient palliative care, Symptom controlBackground
Previous research has shown that patients with advanced
cancer develop severe physical and psychosocial symptoms
as a result of cancer and treatments [1,2]. Among cancer-
related symptoms, cancer-related fatigue (CRF) is the most
common chronic and distressing [2], with a frequency of
60-90% [1]. Since CRF is more severe in advanced stages* Correspondence: syennu@mdanderson.org
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distribution, and reproduction in any mediumthan in early stages of disease, CRF can prevent patients
with advanced cancer from receiving effective cancer ther-
apy [2]. The National Comprehensive Cancer Network
defines CRF as a distressing, persistent, subjective sense of
physical, emotional, and/or cognitive tiredness or exhaus-
tion related to cancer or cancer treatment that is not pro-
portional to recent activity and that interferes with usual
functioning [3]. Despite CRF’s prevalence, severity, and
effects on quality of life in patients with advanced cancer,
available treatment options are limited [4].
Most referrals to outpatient palliative care clinics
(OPC) were made late in the trajectory of the diseased Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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due to late referral and logistics of receiving cancer care
in a comprehensive center away from home. Hence it is
vitally important to obtain prompt control of CRF in a
short period of time. However there limited studies
regarding factors associated with the severity of fatigue
at the initial visit and predictors of improvement in
patients with advanced cancer seen in outpatient pallia-
tive care clinics at first follow-up visit. Such data would
enable researchers to develop treatment strategies to
manage CRF in ambulatory advanced cancer patients.
The aim of this study was to determine factors asso-
ciated with the severity of fatigue and predictors of im-
provement of fatigue at the first follow-up visit in
patients with advanced cancer referred to outpatient pal-
liative care clinic.
Methods
Patient eligibility and assessments
We reviewed the charts of 2071 consecutive advanced
cancer patients (defined as locally advanced or meta-
static) who had received care at the outpatient pallia-
tive care clinic (OPC) at The University of Texas MD
Anderson Cancer Center and had prospectively com-
pleted the Edmonton Symptom Assessment System
(ESAS) questionnaire including the ESAS fatigue score
at the initial visit and subsequent follow-upvisits be-
tween January 2003 and December 2008. These
patients had at least one follow-up visit after the initial
consultation. Only patients who had prospectively
completed an ESAS questionnaire at the initial visit
and at any follow-up visits within 7–30 days of the
initial visit were eligible for inclusion. Of the 2071
patients screened, a total of 1788 met the eligibility
criteria. The patient characterstics and symptoms of
patients with follow-up and those who did not were
compared to determine if the study sample truly repre-
sents the OPC advanced cancer population.
To test the impact of palliative consultation on fatigue
between the initial visit and the subsequent follow-up
visit, we defined improvement of fatigue as a reduction
of ≥2 points from the baseline, which is a threshold
based on previous quality of life studies [7,8].
Process of palliative service and interventions performed
at the outpatient palliative care clinic
Care for all patients in the palliative care clinic was pro-
vided by an interdisciplinary palliative care team led by
board-certified palliative care specialists. All 10 specia-
lists work as a team and provide mutual coverage in
cases of absence or illness to avoid clinic cancellations,
which helps the team maintain a homogeneous approach
to assessment, management, and communication with
patients and their families. The other team membersinclude a registered nurse trained specifically in pallia-
tive care, a pharmacist, a nutritionist, a chaplain, a social
worker, and an advanced nurse practitioner trained in
palliative care and psychiatry who provides counseling
service. Other specialists in services such as wound
management, speech therapy, occupational therapy, and
physical therapy are consulted when needed.
The care of all patients followed a standardized
management plan [9]. Patients and their families were
initially assessed by the registered nurse using ESAS,
Memorial Delirium Assessment Scale (MDAS), CAGE
and constipation and family support questionnaires.
The findings were discussed with a palliative care spe-
cialist, who then interviewed the patients and their
families and performed a physical examination. The
physician and nurse asked appropriate members of the
interdisciplinary team to participate depending on the
individual needs of patients and their families. Most
patients referred to the outpatient palliative care clinic
receive active cancer treatment including targeted ther-
apy. In all patients fatigue was treated as a multidi-
mensional construct irrespective of whether it was due
to disease, cancer treatment or comorbidities. These
interventions and care provided by the interdisciplinary
team complied with palliative care guidelines estab-
lished by the National Comprehensive Cancer Network
and National Consensus Project and have been out-
lined elsewhere [10]. Specifically for the management
of fatigue, the clinic coordinates a comprehensive assess-
ment and management of all associated cancer-related
symptoms such as pain, anorexia, anxiety, depression,
sedation, shortness of breath, and sleep disturbance. The
clinic also provides expressive supportive counseling and
cognitive interventions so that patients and their families
understand the treatment goals. Special emphasis is
placed on medication review and any plans to discon-
tinue medications associated with fatigue and sedation
such as muscle relaxants, benzodiazepines, and antihista-
mines. In addition, the clinic team emphasizes exercise,
light therapy, and methods to maintain and enhance
socialization.
Edmonton symptom assessment system
The ESAS is a simple, validated, and reliable multi-item
instrument developed to measure various symptoms in
patients with advanced cancer [11,12]. The ESAS ques-
tionnaire, visualized graphically as a numerical rating
scale (0–10), was used to evaluate nine items (pain, fa-
tigue, nausea, depression, anxiety, drowsiness, appetite,
well-being, and shortness of breath) and one patient-
specific symptom; the symptom distress score is calcu-
lated by adding the scores for the nine ESAS items. The
patients were asked to rate the average intensity of these
symptoms in the previous 24 hours, with higher scores
Table 1 Patient Characteristics(n = 1778)
Characteristics Number Percentage (%)
Age in years Mean(SD) 58(13)
Median 59
Range 15-90
Gender Male 918 52%
Race Caucasians 1213 68%











Mild (0–3) 293 16%
Moderate (4–6) 909 51%




Abbrevations: SD, Standard deviation.
† Leukemias, Lymphomas, unknown primary, melanoma.
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settings the vast majority of patients are able to
complete ESAS by themselves with minimal assistance.
The ESAS fatigue score was used to measure changes in
fatigue.
The memorial delirium assessment scale
The MDAS is a structured, 10-item clinician-rated scale,
with each item scored as 0–3 and a possible total score
of 0–30, designed to quantify the severity of delirium in
medically ill patients. This tool was originally tested in a
heterogeneous population of cancer patients and
patients without cancer. The MDAS has been validated
and used for the diagnosis of delirium in cancer patients
[13]. Delirium was defined as an MDAS score of ≥7.
MDAS is administered routinely in all patients present-
ing to the OPC as advanced patient are at risk for
delirium.
CAGE questionnaire
The Cut Down, Annoyed, Guilty, and Eye Opener
(CAGE) questionnaire is a simple, four-item screening
survey for alcoholism. Previous studies by our group
showed that patients who scored positively for alcohol-
ism, with positive responses to ≥2 of the four items, had
higher symptom expression than those who scored nega-
tively [14]. CAGE questionnaire is administered rou-
tinely in all patients presenting to the OPC as advanced
patients have severe symptom distress including signifi-
cant pain and are on opioids and psychostimulants.
We received University of Texas MD Anderson Can-
cer Center Institutional Review Board approval for the
study (protocol DR01-0710).
Statistical analyses
Descriptive statistics (means, medians, frequencies, and
percentages) were used to summarize the patients’
symptoms measured by ESAS, CAGE and MDAS and
their demographic characteristics. Comparison of pa-
tient characteristics and symptoms of patients with ini-
tial consult and follow-up visit and patients with no
follow-up visit were compared using t-test, and Fisher
exact t test. Statistical significance was set at p-value
≤0.05. To determine the association between baseline
fatigue and gender, race, cancer site, anemia status, al-
bumin level, and alcoholism status, we calculated sum-
mary statistics for ESAS for each of these variables
and used a Kruskal-Wallis test to determine whether
the distribution of baseline fatigue was the same for
each. We also calculated correlation coefficients to de-
termine the association between age and other baseline
ESAS items.
To determine the predictive factors associated with se-
verity of fatigue at baseline a linear regression modelwas created with the baseline fatigue score as the
dependent variable and all the other baseline ESAS
scores, MDAS score, alcoholism, low albumin (<3.5 g/dl
anemia (hemoglobin <10 g/dl), and primary cancer type
as the independent variables. All variables that were sta-
tistically significant in the univariate analyses (p ≤ 0.10)
were included in the linear regression model.
Finally, a logistic regression model was created to de-
termine whether ESAS score, MDAS score, anemia, low
albumin, alcoholism, or primary cancer type at baseline
was related to improvement in fatigue, with improve-
ment of fatigue defined as a decrease of ≥2 in the ESAS
fatigue score [7]. In these analyses, a p value of <0.05
was considered significant.
Results
Table 1 summarizes the demographic and clinical charac-
teristics of the study population. The 1778 evaluable
patients had a median age of 59 years; 52% were male. The
most common primary cancer types were head and neck
cancer and lung cancer (27%). The median time between
visits was 15 days. The mean (standard deviation) fatigue
score at baseline was 6 (2.39). 1489 patients (80%) reported
moderate or severe fatigue (≥4/10).
Table 2 summarizes the ESAS item scores at the initial
presentation and the first follow-up visit. At the initial
Table 2 ESAS scores at the initial presentation and at the
first follow-up visit











Feeling of Well-being 5(3–7) 4(2–6)
Shortness of breath 2(0–5) 2(0–4)
Sleep disturbance 5(2–7) 4(2–6)
ESAS Symptom distress score 34(24–46) 30(20–41)
ESAS = Edmonton symptom assessment scale.
†Median (25th-75th quartiles).
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of a possible 30; n = 793), the median blood hemoglobin
level was 11.3 g/dl (normal range, 12–16 g/dl; n = 1426),Table 3 Comparison of Patient Characteristics Between Outpa




















Feeling of well-being 5(3–7)
Shortness of Breath 2(0–5)
Sleep disturbance 5(2–7)
ESAS-Symptom distress score 34(24–46)
ESAS = Edmonton Symptom Assessment Scale.
† t-test for age and ESAS; Fisher exact test for other variables.and the median serum albumin level was 3.7 g/dl (nor-
mal range, 3.5-4.7 g/dl; n = 1178). Of the 793 patients
with MDAS data, 31 (1.74%) had delirium according
to MDAS (≥7 of 30). Of 1426 patients, 314 (17.6%)
had anemia (≤10 g/dl), and of the 1178 patients with
albumin data, 192 (10.7%) had low albumin levels
(<3.5 g/dl).
Table 3 shows baseline data for 1788 patients who met
the eligibility criteria and for 283 who had no follow-up
and therefore were not evaluable. The results show that
the patients who were not evaluable had similar charac-
teristics to those evaluated but had lower severity of
ESAS scores.
We found no univariate associations between fatigue and
age (p = 0.06), gender (p = 0.07), race (p = 0.11), type of
cancer (p = 0.32), anemia (p = 0.09) or alcoholism (p = 0.18)
(Table 4). There were correlations between fatigue and se-
verity levels of pain (r = 0.23), nausea (r = 0.31), anxiety
(r = 0.33), depression (r = 0.33), drowsiness (r = 0.29), ap-
petite (r = 0.41), sleep disturbance (r = 0.25), shortness of
breath (r = 0.33), and well-being (r = 0.36) and the total
ESAS symptom distress score (r = 0.54), with p < 0.0001 fortient Palliative Clinic Patients with and without follow-up
























Table 4 Severity of Baseline Fatigue by Patient
Characterstics
N Mean (SD) Median p-value
Gender 0.07
Female 859 6.16 (2.4) 6
Male 918 5.97 (2.38) 6
Race 0.11
White 1009 6.22 (2.27) 6
Black 155 6.36 (2.44) 7
Hispanic 142 5.86 (2.13) 6
Asian 48 5.83 (2.68) 6
Cancer Site 0.32
Breast 93 6.48 (2.2) 7
Gastrointestinal 280 6.23 (2.36) 6
Genitourinary 162 5.99 (2.36) 6
Gynecological 120 6.43 (2.44) 7
Head and Neck, Lung 472 6.12 (2.23) 6
Sarcoma 68 5.79 (2.34) 5.5
Other 176 6.18 (2.32) 6
Anemia 0.09
No 1112(83.4%) 6.02 (2.39) 6
Yes 314(10.7%) 6.26 (2.43) 7
Low Albumin 0.0003
No 986(89.3%) 6 (2.43) 6
Yes 192(10.7%) 6.69 (2.33) 7
Alcoholic 0.18
No 1044(85%) 6.09 (2.43) 6
Yes 184(15%) 6.34 (2.31) 7
Table 5 Independent Predictors of the severity of
Baseline fatigue
Full model Reduced model
Variable B (SE) p-value B (SE) p-value
ESAS items
Pain 0.09 (0.02) < 0.0001 0.09 (0.02) < 0.0001
Nausea 0.09 (0.02) 0.0001 0.09 (0.02) 0.0001
Depression 0.09 (0.03) 0.0017 0.1 (0.02) < 0.0001
Anxiety 0.03 (0.03) 0.31
Appetite 0.17 (0.02) < 0.0001 0.17 (0.02) < 0.0001
Drowsiness 0.08 (0.02) < 0.0001 0.08 (0.02) < 0.0001
Feeling of well-being 0.12 (0.03) < 0.0001 0.12 (0.03) < 0.0001
Shortness of breath 0.14 (0.02) < 0.0001 0.14 (0.02) < 0.0001
Sleep disturbance 0.00 (0.02) 0.96
Low Albumin 0.64 (0.16) < 0.0001 0.66 (0.16) < 0.0001
Male −0.10 (0.12) 0.37
Anemia 0.10 (0.15) 0.52
ESAS- Edmonton symptom assessment scale; B- Beta; SE- standard error.
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associated with fatigue were levels of pain (p < 0.0001),
depression (p = 0.0017), appetite (p < 0.0001), drowsiness
(p < 0.0001), well-being (p < 0.0001), shortness of breath
(p < 0.0001), albumin level (p < 0.0001), and nausea status
(p = 0.0001) (Table 5). In this predictive model, adjusted
r2 = 0.33.
The hierarchical model showed that fatigue did im-
prove at the first follow-up visit (b = −0.009, p = 0.0009),
and the logistic regression model showed that low appe-
tite, genitourinary (GU) cancer, high nausea, and low
shortness of breath were predictors of this improvement
of fatigue by outpatient palliative care consultation.
Baseline low appetite was the strongest predictor of im-
provement in the reduced model (odds ratio [OR] = 1.09
per point; p = 0.0113). Additionally, patients with GU
cancer were more likely to improve in fatigue in the
reduced model (OR = 1.74 per point; p = 0.0458)
(Table 6). The improvement of fatigue was observed in
586 patients (33%). Baseline nausea was the strongestpredictor of improvement in fatigue with higher baseline
nausea scores predictive of improvement (OR = 1.07 per
point; p = 0.0442). In patients with severe fatigue (score
8–10), those with less shortness of breath at baseline
were more likely to improve in fatigue (OR = 0.88 per
point, p = 0.0068).
Changes in fatigue were positively associated with
changes in the other cancer related symptoms as
assessed by ESAS (Table 7).Discussion
Our findings provide preliminary evidence that palliative
care consultation for fatigue for advanced cancer
patients seen at an outpatient palliative care clinic in a
comprehensive cancer center was associated with im-
provement of fatigue at the time of the first follow-up
visit.
Moderate to severe fatigue was common (84%) in the
patients we evaluated. Severity of fatigue at the time of
consultation significantly correlated with all ESAS items,
with pain and appetite having the strongest associations.
These findings are consistent with those from previous
studies [15-23].
One of the strengths of this study, despite its retro-
spective design, is that the fatigue assessment was per-
formed prospectively at both the initial and subsequent
follow-up visits using validated tools in a dedicated
outpatient palliative care clinic. The fatigue assessment
was completed by the patients under the supervision
of nurses trained specifically in palliative care, and
standardized management was provided by a specialist-
led palliative care team in accordance with our
Table 6 Factors associated with improvement of fatigue
Variable Full modela Reduced model
ESAS items OR p-value 95% CI OR p-value 95% CI
Pain 1.05 0.18 0.98 - 1.12 1.05 0.12 0.99 - 1.12
Nausea 1.03 0.51 0.95 - 1.11
Depression 1.02 0.63 0.94 - 1.11
Anxiety 0.98 0.63 0.90 - 1.07
Appetite 1.08 0.01 1.01 - 1.16 1.09 0.01 1.02 - 1.16
Drowsiness 0.95 0.12 0.88 - 1.02 0.96 0.16 0.90 - 1.02
Feeling of well-being 1.09 0.06 1.00 - 1.19 1.08 0.06 1.00 - 1.17
Shortness of breath 0.97 0.45 0.91 - 1.04
Sleep disturbance 1.00 0.93 0.93 - 1.08
Anemia 0.86 0.55 0.52 - 1.43
Low albumin 1.25 0.50 0.66 - 2.37
MDAS items
Consciousness 1.41 0.42 0.61 - 3.28
Disorientation 0.89 0.65 0.55 - 1.46
Memory change 0.78 0.24 0.52 - 1.18
Digit Span 0.71 0.27 0.38 - 1.32 0.69 0.16 0.41 - 1.17
Attention 0.55 0.07 0.28 - 1.07 0.57 0.07 0.31 - 1.05
Disorganized thinking 1.26 0.21 0.87 - 1.81
Perception distrurbance 0.68 0.23 0.35 - 1.29
Delusions 1.20 0.56 0.63 - 2.29
Psychomotor activity 1.34 0.58 0.47 - 3.86
Sleep disturbance 1.06 0.76 0.73 - 1.54
Alcoholism 0.82 0.50 0.46 – 1.46
Cancer Typesb
Breast 0.84 0.66 0.38 – 1.85
Gastrointestinal 1.07 0.80 0.63 - 1.81
Genitourinary 1.92 0.04 1.02 - 3.62 1.74 0.04 1.01 - 2.99
Gynecologic 1.19 0.65 0.56 - 2.53
Sarcoma 1.34 0.47 0.60 - 3.01
Othersc 1.17 0.60 0.65 - 2.11
ESAS: Edmonton symptom assessment scale; MDAS: Memorial delirium assessment scale;
a- Logistic regression model.
b- Reference: Head & Neck or Lung cancer.
c- Unknown primary, melanoma, skin, leukemia, lymphoma, brain.
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ous fatigue assessments [9]. Moreover, this study dif-
fered from earlier studies in its relatively large
population sample size of over 1700 patients and its
focus on factors associated with improvement in fa-
tigue after an outpatient palliative care consultation.
Thus, our findings provide preliminary reference data
about the effectiveness of outpatient palliative care
when standard palliative care is applied to patients
with fatigue.
We found that the severity levels of pain, depression,
appetite, nausea, drowsiness, well-being, and shortnessof breath and albumin level were predictive of the se-
verity of fatigue at the time of the initial consultation.
This information emphasizes the importance of thor-
ough serial assessment of all cancer-related symptoms
for optimal management of fatigue. Future prospective
trials are needed, and fatigue interventions should in-
corporate a multimodal interdisciplinary approach with
targets including the treatment of fatigue-related symp-
toms such as pain, low appetite, and depression in
addition to specific pharmacological interventions for
fatigue. These results are consistent with prior studies
by Hwang et al [20], who found that shortness of
Table 7 Association of change in Fatigue with change in
other ESAS symptoms







Well being .354 <0.001
Shortness of Breath .285 <0.001
Sleep .259 <0.001
ESAS: Edmonton Symptom Assessment Scale.
r: Correlation coefficient.
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irritability predicted fatigue. However, female gender
and low hemoglobin levels, which prior studies have
found to be predictive of severity of fatigue [24-26],
were not associated with fatigue in our study. This re-
sult could be due to the overwhelmingly high symp-
tom burden in our patient population, which may
reduce the role of factors such as anemia [27-29].
We also found that severe anorexia at the initial visit
to the palliative care clinic was associated with improve-
ment of fatigue. This may be due to a strong association
of fatigue with anorexia and cachexia, as both of which
may be caused by the same pathophysiologic process,
namely inflammation [30-32].
We also found that patients with GU cancers (pros-
tate, renal, and transitional cell cancers) were more likely
to improve in fatigue (OR = 1.74 per point, p = 0.045). In
patients with prostate cancer, anorexia cachexia is less
important contributor to fatigue [31]. The authors
speculate that fatigue as a result of androgen deprivation
in prostate cancer patients may be more amenable to
palliative interventions such as exercise [33,34]. How-
ever, further studies are needed to understand this
result.
The results of his study suggest that the changes in
the fatigue scores were positively associated with the
changes in the severity of other ESAS symptoms; these
finding would strongly imply a causal relation between
symptom load and fatigue.
Though the results of this study show preliminary evi-
dence that palliative care consultation was successful in
reducing the severity of fatigue, our model did not cap-
ture all the factors associated with improvement of fa-
tigue, as indicated by adjusted r2 of 0.33. Further studies
are needed.
The results show that the severity of fatigue and other
ESAS symptoms in patients who did not have a follow-
up visit (excluded patients) were milder than in thosewho had at least one follow-up visit (the study sample)
(Table 3). This analysis validates that the results are a
good representation of the patients seen in outpatient
palliative care.
Our study has several limitations, the most import-
ant of which was the retrospective design and its lack
of patients in the setting other than an outpatient pal-
liative care clinic. Another limitation is the use of sin-
gle item measure to assess physical and emotional
symptoms using ESAS. However prior studies have
shown that ESAS items and other single item ques-
tionnaires correlate well with multi-item symptom as-
sessment tools [22,35-38]. Although in the vast
majority cases patient complete the ESAS by them-
selves in outpatient setting there is a possibility that in
the most fatigued patients the nurse or caregiver could
have introduced the bias by assisting the patient. More
research is necessary to address this possibility. This
study also did not assess other well-known factors that
may contribute to fatigue such as inflammatory bio-
markers, which play an important role in fatigue caus-
ation [32,39,40]. Some of the statistically significant
associations in this study may be as a result of mul-
tiple analysis. Future prospective studies are needed to
confirm these findings.
Conclusion
Our findings suggest that fatigue is the most severe
symptom in patients with advanced cancer. Severity
levels of pain, depression, appetite, nausea, drowsiness,
well-being, and shortness of breath and the albumin
level were predictive of the severity of fatigue at the time
of the initial consultation, with pain and low appetite
being the most significant predictors. Genitourinary can-
cer and low appetite at baseline were associated with
successful improvement of fatigue.
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